Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Treatment of cutaneous melanoma: current approaches and future prospects.

Algazi AP, Soon CW, Daud AI.

Cancer Manag Res. 2010 Aug 17;2:197-211. doi: 10.2147/CMR.S6073.

2.

Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.

Davar D, Tarhini AA, Kirkwood JM.

Clin Dermatol. 2013 May-Jun;31(3):237-50. doi: 10.1016/j.clindermatol.2012.08.012. Review. Erratum in: Clin Dermatol. 2013 Jul-Aug;31(4):501.

3.

Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.

Eggermont AM.

Recent Results Cancer Res. 2000;157:178-89. Review.

PMID:
10857171
4.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
5.

The role of adjuvant therapy in melanoma management.

Barth A, Morton DL.

Cancer. 1995 Jan 15;75(2 Suppl):726-34. Review.

PMID:
7805001
6.

Adjuvant treatment of melanoma.

Moreno Nogueira JA, Valero Arbizu M, Pérez Temprano R.

ISRN Dermatol. 2013;2013:545631. doi: 10.1155/2013/545631. Epub 2013 Feb 17.

7.

The impact of surgery on the course of melanoma.

Lejeune FJ.

Recent Results Cancer Res. 2002;160:151-7.

PMID:
12079209
8.

Single-agent interleukin-2 in the treatment of metastatic melanoma.

Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K; Members of the Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Curr Oncol. 2007 Feb;14(1):21-6.

9.

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V.

Cochrane Database Syst Rev. 2013 Jun 18;(6):CD008955. doi: 10.1002/14651858.CD008955.pub2. Review.

PMID:
23775773
10.

Systematic review of medical treatment in melanoma: current status and future prospects.

Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM.

Oncologist. 2011;16(1):5-24. doi: 10.1634/theoncologist.2010-0190. Epub 2011 Jan 6. Review.

11.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

12.

Cutaneous melanoma.

Eggermont AM, Spatz A, Robert C.

Lancet. 2014 Mar 1;383(9919):816-27. doi: 10.1016/S0140-6736(13)60802-8. Epub 2013 Sep 19. Review.

PMID:
24054424
13.

Recent advances in the care of the patient with malignant melanoma.

Reintgen D, Balch CM, Kirkwood J, Ross M.

Ann Surg. 1997 Jan;225(1):1-14. Review.

14.

Current concepts in the management of patients with melanoma.

Lang PG.

Am J Clin Dermatol. 2002;3(6):401-26. Review.

PMID:
12113649
15.

Adjuvant therapy of malignant melanoma.

Dickler MN, Coit DG, Meyers ML.

Surg Oncol Clin N Am. 1997 Oct;6(4):793-812. Review.

PMID:
9309094
16.

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group.

Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20.

PMID:
21256809
17.

Patterns of failure following surgical resection for malignant pleural mesothelioma.

Jänne PA, Baldini EH.

Thorac Surg Clin. 2004 Nov;14(4):567-73. Review.

PMID:
15559064
18.

Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.

Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, Paumier V, Lefeuvre-Plesse C, Rioux-Leclerc N, Mosser J, Oger E, Adamski H, Galibert MD, Lesimple T.

J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1530-8. doi: 10.1111/jdv.12910. Epub 2015 Jan 26.

PMID:
25623140
19.

Treatment of malignant melanoma.

Durán García E, Santolaya R, Requena T.

Ann Pharmacother. 1999 Jun;33(6):730-8. Review.

PMID:
10410188
20.

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK.

Eur J Cancer. 2014 Oct;50(15):2668-76. doi: 10.1016/j.ejca.2014.06.009. Epub 2014 Jul 25.

PMID:
25070294

Supplemental Content

Support Center